Navigation Links
Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
Date:5/16/2014

SOUTH PLAINFIELD, NJ May 16, 2014 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in % predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. The collective data from this trial, including retrospective and subgroup analyses support the conclusion that ataluren was active and showed clinically meaningful improvements over placebo in these trials.

"The overall data from this trial are promising. Patients on ataluren experienced fewer pulmonary exacerbations and showed a stabilization in their FEV1 results, particularly in the subgroup of patients that did not use chronic inhaled aminoglycosides. Such stabilization of disease is an important clinical endpoint, particularly for this patient population that has one of the most severe forms of CF. CF patients with nonsense mutations do not produce any functional CFTR protein and therefore generally have a more severe form of cystic fibrosis. Current treatments for nonsense mutation cystic fibrosis focus on alleviating symptoms and reducing infections, whereas ataluren targets the underlying cause of disease," stated Michael Konstan, M.D., lead study investigator and Chairman of Pediatrics at from University Hospitals Rainbow Babies and & Children's Hospital in Cleveland, Ohio.

The Phase 3 double-blind, placebo-controlled study, which was conducted across 11 countries, compared ataluren (n=116) to placebo (n=116) in nmCF patients. The primary endpoint, the relative change from baseline in %-predicted FEV1 at 48 weeks, showed a positive trend favoring ataluren versus placebo, and a larger effect in patients not receiving chronic inhaled tobramycin. In the
'/>"/>

Contact: Katelyn McCarthy
katelyn.mccarthy@uhhospitals.org
216-767-8582
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
2. Celldexs Phase 1 study of CDX-1401 published in Science Translational Medicine
3. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
4. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
5. North Shore-LIJ Completes Last Phase of $50M Upgrade of its Diagnostic Imaging Systems, $12M for GE Low-Dose CT Scanners to Reduce Patients’ Radiation Exposure
6. Stryker Hip Lawsuit News: Phase II of Mediation Set to Begin in Stryker Hip Recall Litigation Underway in New Jersey State Court, Bernstein Liebhard LLP Reports
7. LFoundry Rousset LF 110 Flash Technology Enters Industrial Phase
8. “Final Phase Fat Loss” Introduces To People An Innovative Bodyweight Training Program – Vinamy
9. CS Caregiver University Announces Its First Phase of Inductive Training for the Month of October
10. Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy
11. For first time, drug developed based on zebrafish studies passes Phase I clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... emissions will reduce other harmful air pollution and ... new study released today. The research shows that, ... final Clean Power Plan, the power plant standards ... and hundreds of heart attacks in the United ... Co-benefits of Carbon Standards for Existing Power Plants, ...
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 VisitandCare.com ... in Turkey has gone up more than 79 percent ... medical tourism company also reported total revenue tripled for ... , The company’s professional strategy has allowed them to ... ultimately designed for patient comfort and privacy — with ...
Breaking Medicine News(10 mins):Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... available through Lifeboat,s reseller network; Services seen as complement to ... ... Northglenn, CO (PRWEB) March 5, 2009 -- ImageDoc USA, ... a distribution agreement with Lifeboat Distribution, an international specialty software ...
... patients with better results, lower cost, less discomfort, faster recovery ... ... Boca Raton, FL (PRWEB) March 5, 2009 -- A new ... improve hair transplant surgery for male and female patients., , ...
... and resources for patients and their families , ... ... brain injuries each year through falls, traffic accidents, sports and other ... (BIAA), which is observing National Brain Injury Awareness Month in March ...
... evaluate the effectiveness of current continuing medical education ... recommendations on how those practices need to change ... of CHEST , the peer-reviewed journal of ... of Continuing Medical Education: American College of Chest ...
... also been accepted for publication as an original article ... 4 NewCardio, Inc. (OTC Bulletin Board: NWCI) a ... Ihor Gussak, NewCardio,s Vice President and Chief Medical Officer, ... 58th Annual Scientific Session in Orlando on March 29, ...
... The following is a statement by Matthew ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The House Energy and Commerce Committee today ... historic action to reduce tobacco use by approving ... authority over tobacco products. Today,s 39-13 vote ...
Cached Medicine News:Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2Health News:New NeoGraft™ Device Improves Hair Transplants 2Health News:New NeoGraft™ Device Improves Hair Transplants 3Health News:Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year 2Health News:New CME guidelines advise paradigm shift in physician education 2Health News:New CME guidelines advise paradigm shift in physician education 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 2Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 4Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 2Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 3
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Inquire...
Medicine Products: